Research progress on non-protein-targeted drugs for cancer therapy

Non-protein target drugs, especially RNA-based gene therapies for treating hereditary diseases, have been recognized worldwide. As cancer is an insurmountable challenge, no miracle drug is currently available. With the advancements in the field of biopharmaceuticals, research on cancer therapy has g...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yiwen, Lu, Lu, Song, Feifeng, Zou, Xiaozhou, Liu, Yujia, Zheng, Xiaowei, Qian, Jinjun, Gu, Chunyan, Huang, Ping, Yang, Ye
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10011800/
https://www.ncbi.nlm.nih.gov/pubmed/36918935
http://dx.doi.org/10.1186/s13046-023-02635-y
_version_ 1784906478807678976
author Zhang, Yiwen
Lu, Lu
Song, Feifeng
Zou, Xiaozhou
Liu, Yujia
Zheng, Xiaowei
Qian, Jinjun
Gu, Chunyan
Huang, Ping
Yang, Ye
author_facet Zhang, Yiwen
Lu, Lu
Song, Feifeng
Zou, Xiaozhou
Liu, Yujia
Zheng, Xiaowei
Qian, Jinjun
Gu, Chunyan
Huang, Ping
Yang, Ye
author_sort Zhang, Yiwen
collection PubMed
description Non-protein target drugs, especially RNA-based gene therapies for treating hereditary diseases, have been recognized worldwide. As cancer is an insurmountable challenge, no miracle drug is currently available. With the advancements in the field of biopharmaceuticals, research on cancer therapy has gradually focused on non-protein target-targeted drugs, especially RNA therapeutics, including oligonucleotide drugs and mRNA vaccines. This review mainly summarizes the clinical research progress in RNA therapeutics and highlights that appropriate target selection and optimized delivery vehicles are key factors in increasing the effectiveness of cancer treatment in vivo.
format Online
Article
Text
id pubmed-10011800
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-100118002023-03-14 Research progress on non-protein-targeted drugs for cancer therapy Zhang, Yiwen Lu, Lu Song, Feifeng Zou, Xiaozhou Liu, Yujia Zheng, Xiaowei Qian, Jinjun Gu, Chunyan Huang, Ping Yang, Ye J Exp Clin Cancer Res Review Non-protein target drugs, especially RNA-based gene therapies for treating hereditary diseases, have been recognized worldwide. As cancer is an insurmountable challenge, no miracle drug is currently available. With the advancements in the field of biopharmaceuticals, research on cancer therapy has gradually focused on non-protein target-targeted drugs, especially RNA therapeutics, including oligonucleotide drugs and mRNA vaccines. This review mainly summarizes the clinical research progress in RNA therapeutics and highlights that appropriate target selection and optimized delivery vehicles are key factors in increasing the effectiveness of cancer treatment in vivo. BioMed Central 2023-03-14 /pmc/articles/PMC10011800/ /pubmed/36918935 http://dx.doi.org/10.1186/s13046-023-02635-y Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Review
Zhang, Yiwen
Lu, Lu
Song, Feifeng
Zou, Xiaozhou
Liu, Yujia
Zheng, Xiaowei
Qian, Jinjun
Gu, Chunyan
Huang, Ping
Yang, Ye
Research progress on non-protein-targeted drugs for cancer therapy
title Research progress on non-protein-targeted drugs for cancer therapy
title_full Research progress on non-protein-targeted drugs for cancer therapy
title_fullStr Research progress on non-protein-targeted drugs for cancer therapy
title_full_unstemmed Research progress on non-protein-targeted drugs for cancer therapy
title_short Research progress on non-protein-targeted drugs for cancer therapy
title_sort research progress on non-protein-targeted drugs for cancer therapy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10011800/
https://www.ncbi.nlm.nih.gov/pubmed/36918935
http://dx.doi.org/10.1186/s13046-023-02635-y
work_keys_str_mv AT zhangyiwen researchprogressonnonproteintargeteddrugsforcancertherapy
AT lulu researchprogressonnonproteintargeteddrugsforcancertherapy
AT songfeifeng researchprogressonnonproteintargeteddrugsforcancertherapy
AT zouxiaozhou researchprogressonnonproteintargeteddrugsforcancertherapy
AT liuyujia researchprogressonnonproteintargeteddrugsforcancertherapy
AT zhengxiaowei researchprogressonnonproteintargeteddrugsforcancertherapy
AT qianjinjun researchprogressonnonproteintargeteddrugsforcancertherapy
AT guchunyan researchprogressonnonproteintargeteddrugsforcancertherapy
AT huangping researchprogressonnonproteintargeteddrugsforcancertherapy
AT yangye researchprogressonnonproteintargeteddrugsforcancertherapy

Ejemplares similares